Cheng Chongyun, Liu Miaomiao, Gao Xiaoqin, Wu Dong, Pu Mengchen, Ma Jun, Quinn Ronald J, Xiao Zhicheng, Liu Zhijie
National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Griffith Institute for Drug Discovery, Griffith University, Brisbane, Queensland 4111, Australia.
ACS Omega. 2022 Apr 14;7(16):13925-13931. doi: 10.1021/acsomega.2c00340. eCollection 2022 Apr 26.
The c-Jun N-terminal kinases (JNKs) are evolutionary highly conserved serine/threonine kinases. Numerous findings suggest that JNK3 is involved in the pathogenesis of neurodegenerative diseases, so the inhibition of JNK3 may be a potential therapeutic intervention. The identification of novel compounds with promising pharmacological properties still represents a challenge. Fluorescence thermal shift screening of a chemically diversified lead-like scaffold library of 2024 pure compounds led to the initial identification of seven JNK3 binding hits, which were classified into four scaffold groups according to their chemical structures. Native mass spectrometry validated the interaction of 4 out of the 7 hits with JNK3. Binding geometries and interactions of the top 2 hits were evaluated by docking into a JNK3 crystal structure. Hit had a of 21 μM with JNK3 suggested scaffold 5-(phenylamino)-1-1,2,3-triazole-4-carboxamide as a novel and selective JNK3 binder.
c-Jun氨基末端激酶(JNKs)是进化上高度保守的丝氨酸/苏氨酸激酶。大量研究结果表明,JNK3参与神经退行性疾病的发病机制,因此抑制JNK3可能是一种潜在的治疗干预措施。鉴定具有良好药理特性的新型化合物仍然是一项挑战。对一个由2024种纯化合物组成的化学多样化的类先导支架文库进行荧光热位移筛选,初步鉴定出7个与JNK3结合的命中物,根据其化学结构将它们分为4个支架组。基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)验证了7个命中物中有4个与JNK3的相互作用。通过对接JNK3晶体结构评估了前2个命中物的结合几何结构和相互作用。命中物1与JNK3的解离常数(KD)为21 μM,表明支架5-(苯胺基)-1,2,3-三唑-4-甲酰胺是一种新型的选择性JNK3结合剂。